Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05820399 · ClinicalTrials.gov registry record · NA
Guayusa Extract on Exercise Training
A NA study of Exercise Training and Physical Exertion, sponsored by Nathaniel Jenkins.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT05820399: Completed NA study of Exercise Training and Physical Exertion, sponsored by Nathaniel Jenkins.
NCT05820399 is a NA study of Exercise Training and Physical Exertion that has completed, run by Nathaniel Jenkins. The registered enrollment target is 57 participants, below the 94-participant average among 3 other Exercise Training trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05820399, a NA study of Exercise Training and Physical Exertion, has completed, sponsored by Nathaniel Jenkins.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
Guayusa extract is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (\~20% caffeine, 30% chlorogenic acids, 5% catechins). It is also remarkably low in tannins which are responsible for the bitter taste found in most teas - giving it a sweet flavor profile. As such, it is marketed as an ingredient that can help support energy and performance with potential health-related benefits due to its antioxidant properties. Indeed, ingredients such as these are often consumed by individuals prior to exercise in order to help improve exercise performance, or otherwise to support health-related goals. Whereas several studies have suggested that caffeine and chlorogenic acid consumption may improve performance, mood, and concentration, and some evidence in animals have linked catechin consumption to improved health outcomes, no studies have previous studied whether guayusa extract supplementation helps to support exercise performance in humans. In this study, we will test the whether dietary supplementation with the botanical organic guayusa extract helps support (1) the desire to exercise and exercise performance throughout a 6-week high intensity exercise training program, and thus (2) helps support the physiological adaptations (including body composition, fasting metabolic biomarkers, blood pressure and heart rate, submaximal and maximal exercise performance and fuel metabolism, and changes in the gut microbiome/mycobiome) to a 6-week high intensity exercise training program. Question 1: Does organic guayusa extract supplementation support the desire to train and training load in physically-active women performing a high-intensity exercise training program? Question 2: Does organic guayusa extract supplementation support physiological adaptation to exercise (including body composition, fasting metabolic biomarkers, blood pressure and heart rate, submaximal and maximal exercise perf
Primary Outcome
Desire to Exercise will be assessed Primarily via the Assessment of Exercise Readiness using a 41-item Exercise Readiness Questionnaire.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Organic Guayusa Extract
Study Locations (1)
Iowa
- Integrative Laboratory of Applied Physiology and Lifestyle Medicine - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-09-05 |
| Est. Completion | 2022-11-18 |
| Phase | NA |
What the finished NCT05820399 record still lists
NCT05820399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 94-participant average among 3 other Exercise Training trials with a reported enrollment target (39% lower).
The record links to 3 conditions, with Exercise Training appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05820399 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05820399 about?
NCT05820399 is a clinical study titled "Guayusa Extract on Exercise Training". Guayusa extract is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (\~20% caffeine, 30% chlorogenic acids, 5% catechins). It is also remarkably low in tannins which are responsible for the bitter taste foun...
What is the current status of trial NCT05820399?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2022-09-05. Estimated completion is 2022-11-18.
What conditions does trial NCT05820399 study?
This clinical trial studies the following conditions: Exercise Training, Physical Exertion, Desire to Exercise.
What interventions are being tested in trial NCT05820399?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Organic Guayusa Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05820399?
This trial is sponsored by Nathaniel Jenkins, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05820399 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exercise Training
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI